researchers from the cleveland clinic in ohio have found a link between the drug and treating alzheimer’s disease. their research was published in the medical journal nature aging earlier this week.
“this paper is an example of a growing area of research in precision medicine where big data is key to connecting the dots between existing drugs and a complex disease like alzheimer’s,” dr. jean yaun, program director of translational bioinformatics and drug development at the national institute on aging, which funded the research, said in a release . “this is one of many efforts we are supporting to find existing drugs or available safe compounds for other conditions that would be good candidates for alzheimer’s disease clinical trials.”
advertisement
researchers looked into the effects of two proteins, tau and amyloid, of which the remnants are typically found in alzheimer’s patients’ brains. separately, each protein can cause its own issues in the body such as organ inflammation or shortness of breath. amyloid can build up on the walls of arteries and increase the chance of stroke, the u.s. government website medlineplus says, while tau can accumulate in the brain and potentially aid in developing alzheimer’s, according to the alzheimer’s association .
the scientists found that people who took viagra — or sildenafil — were almost 70 per cent less likely to develop alzheimer’s than those who did not take the drug after a six year follow up. this, compared to other drugs such as the type 2 diabetes drugs metformin and glimepiride, or the blood pressure medicine diltiazem.
advertisement
researchers developed a model of an alzheimer’s patient’s brain using stem cells, and observed sildenafil promoting brain cell growth and simultaneously slowing the spread of tau proteins.
“because our findings only establish an association between sildenafil use and reduced incidence of alzheimer’s disease, we are now planning a mechanistic trial and a phase ii randomized clinical trial to test causality and confirm sildenafil’s clinical benefits for alzheimer’s patients,” cheng said. “we also foresee our approach being applied to other neurodegenerative diseases, including parkinson’s disease and amyotrophic lateral sclerosis, to accelerate the drug discovery process.”
almost 750,000 people in canada have alzheimer’s or another form of dementia, according to the alzheimer’s association .
chris arnold is a toronto-based freelance writer . he can be reached here.
thank you for your support. if you liked this story, please send it to a friend. every share counts.